Influences on HPV vaccine acceptance among men in the Philippines

Journal of Men's Health

Volumn 8, Issue 2, 2011, Pages 126-135

  Young, April M ^a   Crosby, Richard A ^b   Jagger, Kathleen S ^c   Casquejo, Efren ^d   Pinote, Lino ^d   Ybañez, Purita ^d   Casquejo, Luz ^d   Estorgio, Dalinay ^d   Pinote, Lucy ^d  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^c TRANSYLVANIA UNIVERSITY   (United States)

^d Island Ventures Inc BgyBasak   (Philippines)

Author keywords

Acceptance; Attitudes; HPV vaccines; Human papillomavirus; Intention; Male

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; BEHAVIOR CHANGE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DECISION MAKING; EDUCATIONAL STATUS; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PHILIPPINES; PRIORITY JOURNAL; SEXUALITY; VACCINATION;

EID: 79956350932     PISSN: 18756867     EISSN: 18756859     Source Type: Journal    
DOI: 10.1016/j.jomh.2011.01.007     Document Type: Article

References (41)

1. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006, 194(8):1044-1057.
2. Revzina N.V., Diclemente R.J. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS 2005, 16(8):528-537.
3. Palefsky J.M. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010, 46(4S):S12-19.
4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636.
5. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-475.
6. Miralles-Guri C., Bruni L., Cubilla A.L., Castellsagué X., Bosch F.X., De Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009, 62(10):870-872.
7. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl 3). S3/11-25.
8. Hoots B.E., Palefsky J.M., Pimenta J.M., Smith J.S. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009, 124(10):2375-2383.
9. Chin-Hong P.V., Husnik M., Cranston R.D., Colfax G., Buchbinder S., Da Costa M., et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 2009, 23(9):1135-1142.
10. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118(5):2135-2145.
11. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26(3):201-209.
12. Petäjä T., Keränen H., Karppa T., Kawa A., Lantela S., Siitari-Mattila M., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009, 44(1):33-40.
13. Giuliano AR, Palefsky J. Quadrivalent HPV vaccine efficacy against male genital disease and infection. International Papillomavirus Conference: Malmo, Sweden 2009, January 7 [Abstract].
14. Giuliano AR, Palefsky J. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. 2008 Conference of the European Research Organization on Genital Infection and Neoplasia (EUROGIN): Nice, France 2008, November 12-15. [Abstract SS 19-7a].
15. Palefsky J, Giuliano AR. Efficacy of quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. 2008 Conference of the European Research Organization on Genital Infection and Neoplasia (EUROGIN): Nice, France 2008, November 12-15. [Abstract PS 1-3a].
16. Backes D.M., Kurman R.J., Pimenta J.M., Smith J.S. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009, 20(4):449-457.
17. Palefsky J, Male Quadrivalent HPV Vaccine Efficacy Trial Team. Quadrivalent HPV vaccine efficacy against anal intraepithelial neoplasia in men having sex with men. EUROGIN 9th International Multidisciplinary Congress: Monte-Carlo, Monaco 2010, February 17-20. [Abstract SS 19-2].
18. Giuliano A.R., Salmon D. The case for a gender-neutral (universal) human papillomavirus vaccination policy in the United States: point. Cancer Epidemiol Biomarkers Prev 2008, 17(4):805-808.
19. Zimet G.D., Rosenthal S.L. HPV vaccine and males: issues and challenges. Gynecol Oncol 2010, 117(2):S26-S31.
20. Hull S.C., Caplan A.L. The case for vaccinating boys against human papillomavirus. Public Health Genomics 2009, 12(5/6):362-367.
21. de Melo-Martín I. The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection. Oncologist 2006, 11(4):393-396.
22. Thompson M. Who's guarding what? A poststructural feminist analysis of Gardasil discourses. Health Communic 2010, 25(2):119-130.
23. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13(1):28-41.
24. Kim J.J., Andres-Beck B., Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97(9):1322-1328.
25. Joseph D.A., Miller J.W., Wu X., Chen V.W., Morris C.R., Goodman M.T., et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008, 113(10):2892-2900.
26. Jin F., Prestage G.P., Kippax S.C., Pell C.M., Donovan B., Templeton D.J., et al. risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis 2007, 34(7):488-493.
27. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br Med J 2009; 339: (b3884). [Abstract].
28. Brisson M., De Velde N.V., Boily M.-C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12(5/6):343-351.
29. Garnett G.P., Kim J.J., French K., Goldie S.J. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(Suppl 3). S3/178-86.
30. Brewer N.T., Fazekas K.I. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007, 45:107-114.
31. Liddon N., Hood J., Wynn B.A., Markowitz L.E. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health 2010, 46(2):113-123.
32. Young A. HPV vaccine acceptance among women in the Asian Pacific: a systematic review of the literature. Asian Pac J Cancer Prev 2010, 11(3):641-649.
33. Pitts M., Smith A., Croy S., Lyons A., Ryall R., Garland S., et al. Singaporean men's knowledge of cervical cancer and human papillomavirus (HPV) and their attitudes towards HPV vaccination. Vaccine 2009, 27(22):2989-2993.
34. Wong L.P. Role of men in promoting the uptake of HPV vaccinations: focus groups' finding from a developing country. Int J Public Health 2010, 55(1):35-42.
35. WHO/ICO Information Centre on HPV and Cervical Cancer. Human Papillomavirus and Related Cancers in the Philippines. Summary Report Update: September 15, 2010. Barcelona: WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre); 2010. Available at: http://apps.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/PHL.pdf.
36. Rosenstock I. What research in motivation suggests for public health. Am J Public Health 1960, 50:295-302.
37. Azjen I. From intentions to actions: a theory of planned behavior. Action-Control: From Cognition to Behavior 1985, 11-39. Springer, Heidelberg. J. Kuhl, J. Beckmann (Eds.).
38. Domingo E.J., Noviani R., Noor M.R., Ngelangel C.A., Limpaphayom K.K., Thuan T.V., et al. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Vaccine 2008, 26(Suppl. 12):M71-M79.
39. Garland S.M., Cuzick J., Domingo E.J., Goldie S.J., Kim Y.T., Konno R., et al. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine 2008, 26(Suppl. 12):M89-M98.
40. Andrus J.K., Sherris J., Fitzsimmons J.W., Kane M.A., Aguado M.T. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine 2008, 26(Suppl.):K87-K92.
41. Young A.M., Crosby R.A., Jagger K.S., Richardson M.B., Kloha R.A., Safarian V. HPV vaccine acceptability among women in the Philippines. Asian Pacif J Cancer Prev 2010, 11:1781-1787.